ライフサイエンスコーパス: Iressa

1 d another EGFR selective inhibitor, ZD-1839 (Iressa).

2 ZD1839 ("Iressa"), a quinazoline tyrosine kinase inhibitor select

3 inical and clinical investigation is ZD1839 (Iressa), a synthetic anilinoquinazoline capable of inhib

4 GFR) kinase inhibitors, PD153035 and ZD1839 (Iressa), abolished PPARalpha and gamma agonist-dependent

5 Treatments of cells with ERRP or Iressa (an EGFR tyrosine kinase inhibitor) results in el

6 The tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva) have shown anti-tumor ac

7 eptor) tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva) were found to inhibit bo

8 kinase inhibitors (TKIs), such as gefitinib (Iressa) and erlotinib (Tarceva), are limited due to the

9 hat have been used in the clinic, gefitinib (Iressa) and erlotinib (Tarceva).

10 rsible tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva).

11 cancer and confers resistance to gefitinib (Iressa) and tamoxifen.

12 The EGFR inhibitor gefitinib (Iressa) and the phosphatidylinositol 3-kinase (PI3K) inh

13 the EGF receptor (EGFR), such as gefitinib (IRESSA), are effective in a subset of patients with adva

14 Gefitinib (Iressa, Astra Zeneca Pharmaceuticals) is a tyrosine kina

15 of the pivotal phase II trial of gefitinib (Iressa; AstraZeneca, Wilmington, DE) conducted in the Un

16 receptor (EGFR) inhibitor gefitinib (ZD1839, Iressa) blocked cell proliferation at biologically relev

17 nt with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NS

18 the prime directive of our current phase II Iressa/docetaxel trial.

19 proved the EGFR inhibitor gefitinib (ZD1839, Iressa) for the treatment of patients with advanced non-

20 25 and the tyrosine kinase inhibitor ZD1839 (Iressa), from the laboratory to clinical trials.

21 e clinic and have a similar structure (i.e., iressa, gefitinib, and erlotinib).

22 agents in particular (Herceptin, Glivec and Iressa) has exemplified the potential utility of innovat

23 EGFR tyrosine kinase inhibitor, gefitinib ("Iressa"), in non-small cell lung cancer (NSCLC) cells.

24 tor receptor (Egfr) inhibition by gefitinib (Iressa) in males markedly increases hepcidin expression.

25 ZD1839 ("Iressa") is an orally-active, selective epidermal growth

26 ZD1839 (Iressa) is a small-molecular-weight, ATP-mimetic that sp

27 ZD1839 (Iressa) is an ATP-mimetic that inhibits the purified EGF

28 linoquinazoline (4-AQ) derivative gefitinib (Iressa) is an oral epidermal growth factor receptor tyro

29 th sensitivity of lung cancers to gefitinib (Iressa), kinase inhibitor.

30 and L834R EGFR and the effect of gefitinib (Iressa) on the phosphorylation of individual tyrosines.

31 The EGFR inhibitors Iressa or Tarceva are severalfold more potent in inhibit

32 rs of the receptor tyrosine kinase activity (Iressa or Tarceva) has shown clinical efficacy in severa

33 odel with the EGFR kinase inhibitors ZD1839 (Iressa) or PD153035, synthetic anilinoquinazolines with

34 One large phase III trial (the Iressa Pan-Asia Study [IPASS] trial), three smaller phas

35 cancer tumors that responded to single-agent Iressa possessed activating epidermal growth factor rece

36 ified associated with response to gefitinib (Iressa(R)), but seem not to be associated with stable di

37 ceptor tyrosine kinase inhibitor, gefitinib (Iressa), significantly inhibited the abnormal growth of

38 t after the negative result of the phase III Iressa Survival Evaluation in Advanced Lung Cancer (ISEL

39 The phase III Iressa Survival Evaluation in Lung Cancer (ISEL) trial c

40 se for two therapeutic agents of CI-1040 and Iressa, which are currently in clinical use.

41 Gefitinib (Iressa, ZD-1839), a small molecule tyrosine kinase inhib

42 d EGFR tyrosine kinase inhibitor (Gefitinib, Iressa, ZD1839) with respect to its inhibitory effects o

43 ystems, New York, NY) with either gefitinib (Iressa, ZD1839; AstraZeneca, Macclesfield, UK) or erloti

44 Preclinical studies indicate that gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington, DE), an orally

45 single agent the ERBB1 inhibitor, gefitinib (Iressa; ZD1839) showed minimal activity against a panel